drugset / Trial / NCT01090037
TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)
RandomizedParallel-groupDouble-blindTreatment
Summary
In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease: * To confirm the superiority of TRK-100STP over placebo * To determine the recommended therapeutic dose in the 2 doses of TRK-100STP * To assess the safety of TRK-100STP
Timeline
- Start
- 2010-03
- Primary completion
- 2014-08
- Completion
- 2015-01
Publications
- Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4.
- Nakamoto H, Fujita T, Origasa H, Isono M, Kurumatani H, Okada K, Kanoh H, Kiriyama T, Yamada S. A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design. BMC Nephrol. 2014 Sep 19;15:153. doi: 10.1186/1471-2369-15-153.